The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study.
[en] OBJECTIVE: To determine the impact of once-nightly versus twice-daily dosing and beliefs about highly active antiretroviral therapy (HAART) on adherence to efavirenz-based HAART in antiretroviral-naive patients.
METHODS: A multicenter, open-label, 48-week, randomized controlled trial. Participants were randomized to receive once nightly didanosine plus lamivudine, or twice-daily combivir (zidovudine plus lamivudine) both in combination with efavirenz. Medication Event Monitoring Systems were used to compile drug-dosing histories. Beliefs about HAART (necessity and concerns) were measured at baseline using validated questionnaires. Perceptions of HAART intrusiveness were assessed after 4 weeks.
RESULTS: Eighty-seven patients were randomized (44 once-nightly and 43 twice-daily). Overall adherence was higher among the once-nightly arm (P = 0.0327). Eighty-one percent once-nightly and 62% twice-daily patients persisted with treatment for 48 weeks (P = 0.0559). Regimen execution was similar between both arms. Participants were significantly less likely to persist with HAART if their initial concerns about HAART were high relative to their perceived need for treatment (P = 0.025).
CONCLUSIONS: The difference in adherence observed between once-nightly and twice-daily dosing was driven by a difference in persistence with treatment. Psychological preparation for starting HAART should address patients' perceptions of necessity for HAART and concerns about adverse effects to maximize persistence with treatment.
Disciplines :
Immunology & infectious disease
Author, co-author :
Cooper, Vanessa; Department of Practice and Policy, Center for Behavioural Medicine, The School of Pharmacy, University of London, Mezzanine Floor, BMA House, Tavistock Square, London WC1H 9JP, United Kingdom. vanessa.cooper@pharmacy.ac.uk
Horne, Rob; Department of Practice and Policy, School of Pharmacy, University of London, London WC1H 9JP, United Kingdom
Gellaitry, Grace; Department of Practice and Policy, School of Pharmacy, University of London, London WC1H 9JP, United Kingdom
Vrijens, Bernard ; Université de Liège - ULiège > Département de mathématique ; Pharmionic Research Centre, Visé, Belgium
Lange, Anne-Catherine ; Université de Liège - ULiège > Département de mathématique > Probabilités et statistique mathématique ; Pharmionic Research Centre, Visé, Belgium
Fisher, Martin; Department of HIV/GUM, Brighton and Sussex University Hospitals NHS Trust, United Kingdom
White, David; Department of Sexual Health and HIV, Heart of England NHS Foundation Trust, Birmingham, United Kingdom
Language :
English
Title :
The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study.
Publication date :
March 2010
Journal title :
Journal of acquired immune deficiency syndromes (1999)
ISSN :
1525-4135
eISSN :
1944-7884
Publisher :
Ovid Technologies (Wolters Kluwer Health), United States
Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43:939-941.
Gross R, Yip B, Wood E. et al. Boosted PI are more forgiving of suboptimal adherence than non-boosted PI or NNRTI. Presented at: 13th Conference on Retroviruses and Opportunistic Infections; Februay 5-8, 2006; Denver, Colorado.
Molina JM, Journot V, Furco A, et al. Five-year follow-up of once daily HAART with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial). Antivir Ther. 2007;12:417-422.
Johnson MA, Gathe JC, Podzamczer D, et al. A once-daily lopinavir/ ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006;43: 153-160.
Santos J, Palacios R, Lopez M, et al. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine and efavirenz in naive patients: the VESD study. HIV Clin Trials. 2005;6:320-328.
Maggiolo F, Ripamonti D, Gregis G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther. 2003;8:339-346.
Moyle G. The assessing patients' preferred treatments (APPT-1) study. Int J STD AIDS. 2003;14(Suppl 1):34-36.
Parienti JJ, Bangsberg DR, Verdon R, et al. Better adherence with once-daily anti-retroviral regimens: a meta-analysis. Clin Infect Dis. 2009;48: 484-488.
Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. Zidovudine, lamivudine and efavirenz for HIV. N Eng J Med. 2006;354:251-260.
Cooper V, Horne R, Fisher M, et al, The SWEET study group. "Simplification with easier emtricitabine and tenofovir (SWEET): results of a 48 week analysis of patients' perceptions of treatment and adherence", Poster presentation at: The XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico.
Stone V, Hogan J, Schuman P, et al. ARV regimen complexity, self-reported adherence and HIV patients' understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr. 2001; 28:124-131.
Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001; 28:47-58.
Aversa SL, Kimberlin C. Psychosocial aspects of antiretroviral medication use among HIV patients. Patient Educ Couns. 1996;29:219.
Catz SL, Kelly JA, Bogart LM, et al. Patterns, correlates and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19:124-133.
Gebo KA, Keruly J, Moore RD. Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy. J Gen Intern Med. 2003;18:104-111.
Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2:38-45.
Spire B, Duran S, Souville M, et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54:1481-1496.
Chesney M, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG Adherence Instruments. AIDS Care. 2000;12:255-266.
Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr. 1998;18:117-125.
Molassiotis A, Nahas-Lopez V, Chung WY, et al. Factors associated with adherence to antiretroviral medication in HIV-infected patients. Int J STD AIDS. 2002;13:301-310.
Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care. 2000;12:377-386.
Sankar A, Luborsky M, Schuman P, et al. Adherence discourse among African-American women taking HAART. AIDS Care. 2002;14:203.
Horne R. Treatment perceptions and self regulation. In: Cameron LD, Leventhal H, eds. The Self-Regulation of Health and Illness Behaviour. London, United Kingdom: Routledge; 2003.
Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health. 1999;14:1-24.
Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47:555-567.
Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health. 2002;14:1-24.
Horne R, Buick D, Fisher M, et al. Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS. 2004;15:38-44.
Horne R, Cooper V, Gellaitry G, et al. Patients' perceptions of highly active anti-retroviral therapy (HAART) in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr. 2007;45:334-341.
Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence. Cochrane Database of Syst Rev. 2009;Issue 2. CD00001.
Vrijens B, Urquhart J. Patient adherence to prescribed antimicrobial drug dosing regimens. J Antimicrob Chemother. 2005;55:616-627.
Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114-1117.
Cooper V, Buick D, Horne R, et al. Perceptions of HAART among gay men who declined a treatment offer: preliminary results from an interview-based study. AIDS Care. 2002;14:319-328.
Newell A, Mendes da Costa S, Horne R. Assessing the psychological and therapy-related barriers to optimal adherence: an observational study. Presented at: Sixth International Congress on Drug Therapy in HIV Infection; November 17-21, 2002; Glasgow, United Kingdom.
Blaschke TF. Variable adherence to prescribed dosing regimens for protease inhibitors: scope and outcomes. Curr Opin HIV AIDS. 2008;3: 603-607.
Comté L, Vrijens B, Tousset E, et al. Estimation of the comparative therapeutic superiority of QD and BiD dosing regimens, based on integrated analysis of dosing history data and pharmacokinetics. J Pharmacokinet Pharmacodyn. 2007;34:549-558.
Parienti JJ, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine-or efavirenz-based antiretroviral therapy. Clin Infect Dis. 2004;38: 1311-1316.
Ruane P, Lang J, Dejesus E. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. Int J Infect Dis. 2005;9:195-200.
Portsmouth SD, Osorio J, McCormick K, et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. 2005;6:185-190.
Willig JH, Abroms S, Westfall AO, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS. 2008;22:1951-1960.
Molina JM, Podsadecki TJ, Johnson MA. et al. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS Res Hum Retroviruses. 2007;23:1505-1514.
Kleeburger CA, Phair JP, Strathdee, SA, et al. Determinants of heterogeneous adherence to HIV-antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr. 2001;26:82-92.
Gonzalez J, Penedo F, Llabre M, et al. Physical symptoms, beliefs about medications, negative mood, and long-term HIV medication adherence. Ann Behav Med. 2007;34:46-55.
Horne R, Cooper V, Gellaitry G, et al. Identifying the key beliefs influencing uptake and adherence to HAART: Final results of a 12 month, prospective, follow-up study. 11th Annual Conference of the British HIV Association [BHIVA] and the British Association for Sexual Health and HIV [BASHH]. April 20-23, 2005; Dublin, Ireland.
Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28:445-449.
Cooper V, Gellaitry G, Hankins M, et al. The influence of symptom experiences and attributions on adherence to highly active anti-retroviral therapy (HAART): a six month prospective, follow-up study. AIDS Care. 2009;21:520-528.
Mannheimer S, Thackeray L, Hullsiek KH, et al. A randomised comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care. 2008;20:161-169.
Dlamini PS, Wantland D, Makoae LN. HIV stigma and missed doses in HIV positive people in five African countries. AIDS Patient Care STDS. 2009;23:377-387.
Elford E, Ibrahim F, Bukutu C. et al. Disclosure of HIV status: the role of ethnicity among people living with HIV in London. J Acquir Immune Defic Syndr. 2008;47:514-521.
Gatti ME, Jacobson KL, Gazmararian JA, et al. Relationships between beliefs about medicines and adherence. Am J Health Sys Pharm. 2009;66: 657-664.
Wrubel J, Stumbo S, Johnson MO. Antiretroviral medication support among partners of men who have sex with men: a qualitative study. AIDS Patient Care STDS. 2008;22:851-858.
Gazzard BG; BHIVA Treatment Guidelines Writing Group. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Medicine. 2008;9:563-608.
Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-843.
El-Sadr WM, Grund B, Neuhaus J, et al. Risk of opportunistic disease and death after re-initiating antiretroviral therapy in patients previously receiving episodic therapy: a randomised trial. Ann Intern Med. 2008;149: 289-299.
Horne R, Weinman J, Barber N, et al. Concordance, Adherence and Compliance in Medicine Taking: A conceptual Map and Research priorities. London, United Kingdom: National Institute for Health Research (NIHR) Service Delivery and Organisation (SDO) Programme; 2006. Available at: http://www.sdo.lshtm.ac. uk/sdo762004.html. Accessed June 10, 2008.
